If you have been reading about gastric protein and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-02. Numbers and descriptions here follow the published literature rather than marketing material.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Freeze-dried cake or loose powder after lyophilization |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are less durable than the powder |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light; avoid repeated freeze-thaw cycles |
| Identity method | Electrospray mass spectrometry | Compared against the expected mass; paired with sequence or composition analysis |
| Purity method | Reverse-phase HPLC with ultraviolet detection | Reports main-peak percentage rather than peptide content by mass |
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Maulana Shabbir Ahmad Usmani, a respected Deobandi alim (scholar) who held the position of Shaykh al-Islam in Pakistan in 1949, and Maulana Mawdudi of Jamaat-i-Islami played key roles in advocating for an Islamic constitution. Mawdudi insisted that the Constituent Assembly declare the "supreme sovereignty of God" and the supremacy of the shariah in Pakistan. The efforts of Jamaat-i-Islami and the ulama led to the passage of the Objectives Resolution in March 1949. This resolution, described by Liaquat Ali Khan as the second most significant step in Pakistan's history, affirmed that "sovereignty over the entire universe belongs to God Almighty alone and the authority which He has delegated to the State of Pakistan through its people for being exercised within the limits prescribed by Him is a sacred trust". It was later included as a preamble to the constitutions of 1956, 1962, and 1973. Democracy faced setbacks due to the martial law imposed by President Iskander Mirza, who was succeeded by General Ayub Khan. After adopting a presidential system in 1962, Pakistan witnessed significant growth until the second war with India in 1965, resulting in an economic downturn and widespread public discontent in 1967. In 1969, President Yahya Khan consolidated control, but faced a devastating cyclone in East Pakistan resulting in 500,000 deaths. In 1970, Pakistan conducted its first democratic elections since independence, intending to transition from military rule to democracy.
== History == The 5-HT2c receptor agonist Fenfluramine (market names Pondimin, Ponderax and Adifax) was discovered in 1972 as a result of research performed to identify anorectic compounds lacking the effects of psycho-stimulants and sympathomimetic agents (such as amphetamines). Prior to the discovery of fenfluramine, amphetamines were the primary form of anorectic drugs available, however the side effects made them difficult to use. Fenfluramine's anorectic effect is achieved through an increase in serotonin levels, imparting a sensation of fullness, which leads to a lower intake of food. Fenfluramine was sold as a racemic mixture of two enantiomers, dexfenfluramine and levofenfluramine. In 1994, sales of the combination drug Fen-phen (fenfluramine and phentermine) increased dramatically, as this combination produced substantial and apparent synergistic effect in promoting weight loss. Subsequently, reports of severe side effects associated with heart valve abnormalities and an increased risk of pulmonary hypertension resulted in a decision to remove products containing fenfluramine from the U.S. market, and then from other markets around the world. Dexfenfluramine inhibits serotonin reuptake, stimulating the release of serotonin. In 1996, dexfenfluramine became the first long-term treatment anti-obesity medication approved in the US; adverse effects observed during clinical trials included dry mouth, diarrhea and drowsiness. In the mid-1990s the US FDA approved dexfenfluramine as a weight loss drug.
== Epidemiology == In the United States, about 2.5% of the population has moderate to severe valvular heart disease. The prevalence of these diseases increase with age, and 75 year-olds in the United States have a prevalence of about 13%. In industrially underdeveloped regions, rheumatic disease is the most common cause of valve diseases, and it can cause up to 65% of the valve disorders seen in these regions.
A sizable number of Freedmen "were ignorant of the treaty clause which provided for their right of incorporation into the tribe." In the 20th century, the Cherokee Nation passed a law to limit membership to descendants of those listed as "Cherokee by blood" on the Dawes Rolls, excluding numerous African Americans and Afro-Cherokees who had been members of the tribe. In a recognition of Cherokee sovereignty, in 1989 the federal court in the Freedmen case of Nero v. Cherokee Nation held that the Cherokee Nation could legally determine its own citizenship requirements, even if that meant excluding descendants of Freedmen who had formerly been considered citizens.
On June 28, 2005, helped by new menu items and increased advertising exposure, Sonic Corp. reported double-digit increases in net income and revenue in the third quarter that year. On January 5, 2005, the company started to install card readers in the drive-in stalls at its 544 company-owned locations by the end of January that year. In 2007, the company opened its first stores in the Northeastern United States, in Waretown, New Jersey. In 2009, Sonic partnered with DonorsChoose.org on a collaborative effort, Limeades for Learning, the chain's first systemwide cause marketing initiative. Public school teachers request needed supplies and materials and Sonic customers vote on how to allocate over $500,000 each autumn. In the first seven years of the program, Sonic and its franchisees donated more than $6 million and impacted learning for more than 349,000 students nationwide. In September 2009, Omar Janjua joined the company as president of its restaurant operating subsidiary, Sonic Restaurants, Inc. and left in 2015. Despite growth into new markets outside their traditional footprint, the company was hit hard by the recession of 2008–2009. In 2009, the brand had multiple quarters of declines in same-store sales. Plans to bring Sonic to Alaska had not yet come to fruition. On October 26, 2015, Sonic opened its first Rhode Island location in Smithfield, reporting to have received 500 orders on its opening day. In the mid-2010s, the company began a refranchising effort and began to add to its numbers of stores again.
Sources: en.wikipedia.org
=== Vascular === Elabela is expressed by midline tissues (such as the notochord in zebrafish and neural tube in mammals) during organogenesis. There it serves as a chemoattractant to angioblasts expressing APLNR at their cell surface. This participates in the formation of the first and secondary vessels of the vascular system.
==== Types of drug controls ==== There are two different types of controls that can be conducted in competition or in training. It is important that tests are conducted by independent organizations that treat each athlete equally, indifferent of fame or nationality.
He was succeeded by Kazuo Ito as president. In April 2002, Ajinomoto reorganized itself into food, amino acid, and medicine divisions, and owned subsidiaries for frozen foods, fats, and oils. In February 2003, Ajinomoto and Unilever completed a joint venture agreement in six countries and regions of Asia. Because of this, Ajinomoto launched the brand VONO to replace its use of the Knorr brand, and in the process established its own brand identity. In July 2003, Ajinomoto bought the French company Orsan from the UK-based Tate and Lyle Group, renaming Orsan to AJI-NO-MOTO Foods, Europe. In November 2005, AJI-NO-MOTO Pharmaceuticals USA, Inc. was liquidated, and its assets and functions were merged into AJI-NO-MOTO Pharmaceuticals, Europe. In January 2006, Ajinomoto bought the cooking sauce and condiments manufacturer Amoy Food from the French dairy company Groupe Danone. In 2009, the company released "Ajinomoto" to commemorate the 100th anniversary of its foundation.
4,500 Boers surrendered and much equipment was captured, but as with Roberts's drive against Kruger, these losses were of relatively little consequence, as the hard core of the Boer armies and their most determined and active leaders remained at large. From the Basin, Christiaan de Wet headed west. Although hounded by British columns, he succeeded in crossing the Vaal into western Transvaal, to allow Steyn to travel to meet their leaders. There was much sympathy for the Boers in Europe. In October, President Kruger and members of the Transvaal government left Portuguese East Africa on the Dutch warship De Gelderland, sent by the Queen Wilhelmina of the Netherlands. Paul Kruger's wife, however, was too ill to travel and remained in South Africa where she died on 20 July 1901 without seeing her husband again. President Kruger first went to Marseille and then to the Netherlands, where he stayed before moving to Clarens, Switzerland, where he died in exile in 1904.
==== MeSH D12.125.837 – serine ==== MeSH D12.125.837.075 – azaserine MeSH D12.125.837.150 – cycloserine MeSH D12.125.837.225 – droxidopa MeSH D12.125.837.300 – enterobactin MeSH D12.125.837.800 – phosphoserine
Sources: en.wikipedia.org
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.
It describes the share of the chromatographic signal belonging to the main peak, not the mass fraction of peptide in the vial. Water, counter-ions such as acetate or trifluoroacetate, and residual solvents account for part of the weight of a lyophilized lot. Peptide content by mass is a separate measurement and is often reported alongside purity.
Mass spectrometry is the primary check, because the measured mass can be compared with the expected value for the fifteen-residue chain. Sequence analysis or amino acid composition provides an independent confirmation. Purity testing alone does not establish identity, since a mixture of unrelated short peptides can still produce a clean-looking chromatogram.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.